Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
This study reveals that elevated reflux secondary bile acids in Barrett’s esophagus influence the esophageal microbiome and gene expression, highlighting potential mechanisms underpinning progression to esophageal adenocarcinoma.
Intercept Pharmaceuticals withdraws OCALIVA from the US market following FDA demands due to safety concerns and lack of proven efficacy in PBC, prompting suspension of related clinical trials and significant shifts in therapeutic landscape.
AI-assisted digital pathology improves inter-pathologist agreement on fibrosis staging in metabolic dysfunction-associated steatohepatitis (MASH), enhancing clinical trial accuracy and efficiency.
A phase Ib/IIa trial demonstrated that HEC88473, a novel GLP-1/FGF21 dual agonist, is generally safe, effectively reduces liver fat, and improves glycemic and lipid profiles in MASLD patients with type 2 diabetes within five weeks of treatm
AZD2693, a liver-directed antisense oligonucleotide, safely reduces PNPLA3 expression and liver fat in homozygous PNPLA3 148M carriers with metabolic dysfunction-associated steatohepatitis, signaling promise for precision treatment in this
This phase I study evaluates rapirosiran, an RNA interference therapeutic targeting HSD17B13, demonstrating safety, tolerability, and significant liver mRNA reduction in patients with metabolic dysfunction-associated steatohepatitis (MASH).
The THEMATIC phase II trial demonstrates that fecal microbiota transplantation (FMT) is safe and reduces HE recurrence in cirrhosis, independent of dose, route, or donor diet, with gut microbiota engraftment linked to clinical outcomes.
Lanifibranor, a pan-PPAR agonist, significantly reduces liver fat and improves insulin sensitivity at multiple tissue sites in type 2 diabetes patients with MASLD, offering a new therapeutic avenue to address underlying metabolic dysfunctio
A phase IIb trial of the FFAR1/FFAR4 agonist icosabutate in MASH shows encouraging fibrosis improvement and biomarker responses despite not meeting the primary endpoint, supporting further development.
The phase IIb ICONA trial evaluated icosabutate, a dual FFAR1/FFAR4 agonist, in patients with MASH, showing fibrosis improvement without meeting the primary endpoint, and supporting further development particularly in advanced fibrosis and
Losing weight doesn’t always mean improving fatty liver disease. Discover why strict diets lacking essential proteins can worsen liver health and learn practical dietary strategies to manage and reverse fatty liver effectively.
Intraduodenal calcium at doses up to 1000 mg amplifies the anorexigenic effects of L-tryptophan by boosting gut hormones CCK, GLP-1, and PYY, reducing energy intake in obese males, highlighting a novel adjunctive approach for appetite regul
A multicenter trial demonstrated that integrating AI-based computer-aided detection with water exchange colonoscopy significantly increases adenomas per colonoscopy without prolonging procedure time or increasing non-neoplastic lesion detec
A randomized trial demonstrates that leaving small non-neoplastic colorectal polyps in situ with AI-assisted optical diagnosis is as safe and effective as systematic removal, supporting less invasive colonoscopy strategies.
A large UCLA Health randomized clinical trial found that usual care via mailed FIT outreach outperformed active choice strategies in colorectal cancer screening uptake among adults aged 45 to 49 years, highlighting the challenges in engagin
Explore how carbohydrates, proteins, and fats affect fatty liver disease and learn evidence-based dietary and lifestyle recommendations to manage and reverse this common condition.
Linarin shows promise in mitigating NAFLD by enhancing autophagy via PI3K/Akt/mTOR inhibition, reducing inflammation, and restoring gut microbiota balance, alongside activating the PDE4D/cAMP/PKA/CREB pathway to improve hepatic lipid metabo
A comprehensive Swedish study reveals that patients with microscopic colitis face a significantly higher risk of developing psychiatric disorders such as depression and anxiety, underscoring the importance of holistic clinical management.
This multicentre trial shows sequential use of COX-2 inhibitors parecoxib and imrecoxib significantly reduces severe acute pancreatitis (SAP) incidence, shortens organ failure duration, lowers local complications, and decreases 30-day morta
A large multicohort study demonstrates that the China-CLIF framework outperforms existing criteria in diagnosing and predicting mortality in acute-on-chronic liver failure across all major aetiologies, with global applicability.
Open language-specific specialty feeds and department pages.